149 related articles for article (PubMed ID: 24347984)
1. Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis.
Giofrè C; Scicchitano F; Palleria C; Mazzitello C; Ciriaco M; Gallelli L; Paletta L; Marrazzo G; Leporini C; Ventrice P; Carbone C; Saullo F; Rende P; Menniti M; Mumoli L; Chimirri S; Patanè M; Esposito S; Cilurzo F; Staltari O; Russo E; De Sarro G;
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S55-60. PubMed ID: 24347984
[TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis.
Scicchitano F; Giofrè C; Palleria C; Mazzitello C; Ciriaco M; Gallelli L; Paletta L; Marrazzo G; De Fazio S; Menniti M; Curia R; Arena C; Chimirri S; Patanè M; Esposito S; Cilurzo F; Staltari O; Russo E; De Sarro G
J Res Med Sci; 2012 Sep; 17(9):872-5. PubMed ID: 23826016
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
[TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance in Italy: An overview.
Mazzitello C; Esposito S; De Francesco AE; Capuano A; Russo E; De Sarro G
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S20-8. PubMed ID: 24347976
[TBL] [Abstract][Full Text] [Related]
5. Nexavar(®)-related adverse reactions: Calabrian (Italy) experience for sorafenib exposition in 2012.
Cilurzo F; Staltari O; Patanè M; Ammendola M; Garaffo C; Di Paola ED
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S86-9. PubMed ID: 24347990
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
7. Drug-related deaths: an analysis of the Italian spontaneous reporting database.
Leone R; Sottosanti L; Luisa Iorio M; Santuccio C; Conforti A; Sabatini V; Moretti U; Venegoni M
Drug Saf; 2008; 31(8):703-13. PubMed ID: 18636789
[TBL] [Abstract][Full Text] [Related]
8. The safety of ketoprofen in different ages.
Carbone C; Rende P; Comberiati P; Carnovale D; Mammì M; De Sarro G
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S99-S103. PubMed ID: 24347993
[TBL] [Abstract][Full Text] [Related]
9. Knowledge, attitudes and practice regarding pharmacovigilance and adverse drug reaction reporting among physicians and pharmacists in Egypt: a step toward personalized medicine implementation.
Aziz AA; Rogers S; Hassanien O; Shalaby L; Nagy M
Per Med; 2022 Nov; 19(6):495-507. PubMed ID: 36239598
[TBL] [Abstract][Full Text] [Related]
10. Current Scenario and Future Prospects of Adverse Drug Reactions (ADRs) Monitoring and Reporting Mechanisms in the Rural Areas of India.
Shukla S; Sharma P; Gupta P; Pandey S; Agrawal R; Rathour D; Kumar Kewat D; Singh R; Kumar Thakur S; Paliwal R; Sulakhiya K
Curr Drug Saf; 2024; 19(2):172-190. PubMed ID: 37132145
[TBL] [Abstract][Full Text] [Related]
11. Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug's safety profile.
Motola D; Melis M; Lo Bianco S; Buccellato E; Biagi C; Vaccheri A
Expert Opin Drug Saf; 2014 Jul; 13(7):867-73. PubMed ID: 24809453
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy.
Leporini C; De Sarro C; Palleria C; Caccavo I; Piro B; Citraro R; De Sarro G
Drug Saf; 2022 Nov; 45(11):1381-1402. PubMed ID: 36112324
[TBL] [Abstract][Full Text] [Related]
14. Informatics applied to pharmacovigilance: Future perspectives.
Menniti M; Menniti A; Patanè M; Esposito S; Giofrè C; Aiello R; Russo E
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S43-6. PubMed ID: 24347981
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
[TBL] [Abstract][Full Text] [Related]
16. Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network.
Gozzo L; Navarria A; Benfatto G; Longo L; Mansueto S; Sottosanti L; Pani L; Salomone S; Drago F
Clin Drug Investig; 2017 Nov; 37(11):1067-1081. PubMed ID: 28856572
[TBL] [Abstract][Full Text] [Related]
17. Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study.
Leone R; Moretti U; D'Incau P; Conforti A; Magro L; Lora R; Velo G
Drug Saf; 2013 Apr; 36(4):267-76. PubMed ID: 23475583
[TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance practice among pediatric neurologists from Poland and Germany.
Kopciuch D; Kus K; Niśkiewicz I; Fliciński J; Zaprutko T; Ratajczak P; Nowakowska E; Hoffmann K; Koligat-Seitz A; Bryl W; Paczkowska A
BMC Med Educ; 2023 Aug; 23(1):547. PubMed ID: 37528387
[TBL] [Abstract][Full Text] [Related]
19. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
[TBL] [Abstract][Full Text] [Related]
20. Monitoring drug safety in Astrakhan, Russia.
Kirilochev OO; Dorfman IP; Umerova AR
Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
